WO2024193449 - ANTI-HER3 AND ANTI-MET ANTIBODIES AND USES THEREOF
National phase entry:
Publication Number
WO/2024/193449
Publication Date
26.09.2024
International Application No.
PCT/CN2024/081833
International Filing Date
15.03.2024
Title **
[English]
ANTI-HER3 AND ANTI-MET ANTIBODIES AND USES THEREOF
[French]
ANTICORPS ANTI-HER3 ET ANTI-MET ET LEURS UTILISATIONS
Applicants **
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
Inventors
LI, Zhuolin
SHANG, Chengzhang
YANG, Yi
SHEN, Yuelei
Priority Data
PCT/CN2023/082295
17.03.2023
CN
PCT/CN2023/083790
24.03.2023
CN
PCT/CN2023/125481
19.10.2023
CN
PCT/CN2024/075481
02.02.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5040 | |
| EPO | Filing, Examination, Granting | 91576 | |
| Japan | Filing, Examination, Granting | 4692 | |
| South Korea | Filing, Examination, Granting | 7428 | |
| USA | Filing, Examination, Granting | 29390 |
Total:
138,126
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Provided are anti-HER3 (human epidermal growth factor receptor 3) and anti-MET antibodies, and the related antigen-binding fragments thereof, antibody-drug conjugate(ADC) derived therefrom, and the uses thereof.[French]
L'invention concerne des anticorps anti-HER3 (récepteur du facteur de croissance épidermique humain 3) et anti-MET, et leurs fragments de liaison à l'antigène associés, un conjugué anticorps-médicament (ADC) dérivé de ceux-ci, et leurs utilisations.